Effetto dei liposomi di fosfolipidi ipotalamici in pazienti trattati con sulpiride o aloperidolo

668 views

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
668
On SlideShare
0
From Embeds
0
Number of Embeds
68
Actions
Shares
0
Downloads
3
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Effetto dei liposomi di fosfolipidi ipotalamici in pazienti trattati con sulpiride o aloperidolo

  1. 1. JEUTICA I I l Num. 1 I THE EFFEcr OF HYPOTHALAMlC PHOSPHOLIPID LIPOSOMES IN PAT1ENTS TREATED WITH SmPJRIDE OR HALOPERlOOL . volume of distribution 5. E. AGUGLIA, C. CALANDRA, V. RAPISARDA rnagement of hyperten- rdy. 15 i I ltmittIJe of Ps~çhittt11 (Remi 01 Dsp4rlmenl: Pro/. ·V. Rapkaraa)J UniV6rfiJy of Catania (11411) potassfum conserving / ... D. MAUGERI 23 InJJituie o/ Gero1Jlolccy (Read of Departmento p.rot. L. Motta),:>SEI, G. ROMAN8!:LI, UnitJt1rsity o/ Cd/anta (1ta1:y)IESAN, M. MOTOLESE,otory heart fa/lure • 31 Summary of cyprohepladlne and 43 We evaluated the effieacy of treatment with hypothalamic phospholipid Iiposomes in depressed patieots treated with sulpiride and io schizophrenieERICHETII, ":i . patients !reated with haloperidol in comp,arison with patients having theJJlnical trla! of dihydro· 53 J . --1. same disorders and !reated with· the same psychotlopic ~ alone. The results were assessed nsing the tests of Hamilton, CassllJl(>, Zoog and Witten·ZAGUI~~k , homo Plasma prolactin Ievels were monitored iJr order to detect aetivity of hypothalamic phospholipids on drng-induced hyperprolactinaemia.~èute appendlcltls wlth The resu!ts obtained showed not only that the therapeutic associationn of cfif}damycin phos~ of hypotbalamic phospholipid Iiposomes did not negatively inJIuence the 69 therapeutie potentiai of the two. psychotropic drngs, but indeed eohaucedH their efficacy.mQdul® 200 79 The increase of plasma proIactin levels produced· by sulpiride was notnog/ycate pressurlsoo modified by treatment with hypothaIamic phospholipid Iiposomes, whereas 89 .~ this increase was conside,ably blunted in patients receiviog haioperid.ol.o dlsorders and post- 97 !NTRODUcrIONJOMANGEl/meni In tha trt8tment During Iecent yeaIs pharmacologica1 pIOgICSS has peImitted an improved ..~ . 107 symptomarie ·appIoaeh co mental illnesses. Drugs sueh as haloperidol have made the control of halincinatory phenomena possible [l}, while drugs suehnad/ne In varlous skin 119 a, sulpiride have pIoved to have a good therapeurle effeef in depression, psy. chosomatic diseases and psychomoror inhibition [2, 3]. Howevèr, tbe pIoblem of undesiIable side effeets hils remained. Acta Therapeutica lO (1984) 133-•..•., - - - - - - - - . -----:;:te----.
  2. 2. i "--"--+:.,- .._.... __.-....._ _. _ - - J B. AGUGLIA, C. CALANDRA, n. MAUGERI. V. RAPISAR:OA i I Morot side effecrs can be largely controlled by the use cri anrlcholinergic phtenia. The 15 depressed : ! !druga, but these do nOt have the same acrion on othet side effeets which to diffetent therapeutic proIdepend on a neuro·endoctine mechanism [4, 5). Recent data in the literarurehave shown that phospholipids can interiere witli this mechanism [61. . Group A, including i l( sulpitide Im. (400 mg pet d I Mter only seven days of trealment with sulpidde, plasma prolaetin levelsundergo a norable increase. The administtation of haloperidol causeS a rapidincrease in pt;laetin levels afte< only 90 minutes. CASACCHIA [6} has fot a pedod of 28 da ys; ft. • hypothalamic phospholipid administrarion at 8.00 a.m. , Idemonstrated that phospholipid Iiposomes may be concemed with tbis in·crease. ~. Group B (the control i received only sulpiride given . I Our aim was to evaluate the experimental validìty cri these recent dara. of 28 days. IPHOSPHOLIPlD LIPOSOMES The 15 patìents sufferi I GtOUP A includìng lO parle 5 patients, 3 women and ; I The use of thin !ayer chromatography has been able to provide informa- haloperìdol and were treate don ahoot the chemical struetUre of the various classes of phospholipids. Interpretation of the cole of the phospholipids has opened up a fascinating Both the sulpitide and field of tesearch. Phospholipid molecules, when organi2ed in the form cri out period lasring 7 days, , Iiposomes, ate able to cross vhe blood-hrain barder [7] and to aet at the psychodiagnostic tests wete , level of the centraI nervous system; their effects are as follows : diagnosric tests wete repeate<- stimulation of the endogenous synthesis of phospholìpids by the activation same assessments were carri of dddil-transferase;- activation of adenylcyclase [8]; RESULTS- increase of the cerebral content of glucose [9, W];- aerJvation cri the dopaminergic pathways [11, 12]. The deptessed patienrs Studies by GREGORIADIS [13} and PAPAHADIOPOULOS [14] have esta- values of the various tests. :blished that the charaeteristic properties of Iiposomes ate related to physical psychodiagnosric tests on eastability and the capadty to interaer by fusion with biological membranes. piride and hypothalamie ph In OUt experiments we used Iiposomes of hypothalamic origin, charac- with sulpitide alone (Groupterized by the presence of long polyunsaturated hydrocarbon chains and nega- The score trend evaluorlvely charged gtoups. by means of Cassanos tesI However, the petcentage inMATERIALS AND METHODS liposomes were associated w the gtOUp treated with sulpil Thitty padents, age<! 20·52 years, were included in the srudy. Por An even cIearer impr<psychiatdc diagnosis we used the Research Diagnostic Cdteria (RDC) (15). and Hamilton tests in patPsychopathological status was ra<ed by mean of Hamiltons scale, Cassanos phospholipid liposomes tOBresr and Zungs arociery test for depression and Wirrenborn$ test for schizo- 15.2 % and 35.1 % respecr:phrenia. Of these patients, 15 suffered from depression aod 15 ftom schizo- sulpitide alone (Fig. 1). Acta Therapeutica 10 (1984) Acta Therapeutica 10 (198· . "}
  3. 3. l ..,. "!.·: ,".;: :". c,. -,." EFFECT OF"HYPOTHALAMIC "PHOSPHOUPID LlPOSOMES ed by the use cf antichoIinergic phrenia. The 15 depressed patienrs were divided into 2 groups and subjected·n On other side effeets whieh ro different therapeutic programmes. ]. Recent data in the literature.ith chis mechanism [6]. Group A, including lO parienrs, 6 women and 4 men, was treated with sulpiride Lm. (400 mg per day in 2 administrarions at 8.00 a.m. and 1.00 p.m.)llpiride, plasma prolactin levels for a period of 28 days; from the 7th day of treatrnent 400 mg per day of1 of haloperidol causes a rapid hypothalamic phospholipid liposomes was also given in a single inrravenousminutes. CASACCHIA [6] has administrarion at 8.00 "-m.y be concerned with this in- . , Group B (the control group) including 5 padenrs,3 women and 2 men,li vallidity of these recent dara. received only sulpiride giveo in the same way, for the whole observadon perio<! of 28 days. The 15 patieors suffering from schizophrenia were divided into 2 groups. Group A including lO parienrs, 6 women and 4 men, and Group B including 5 parienrs, 3 women and 2 men, were administered with 4 mg per day of; been able to provide informa- haloperidol and were rreated in the same way as the depressed padenrs.rious c1asses of phospholipids.s has opened np a fasdnadng Both the sulpiride and the haloperidol were administered after a wash-Len organized in the form of out perio<! lasdng 7 days, at che end of whieh baseline prolactin levels and barrier [7] and to aet at the psychodiaguosdc tesrs were evaluated. On the 7th day cf treatroent the psycho-= are as follows :phospholipids by che aetivation diagnosdc tesrs were repeated and plasma prolacdn levels were detetInined; the same assessments were carried out at me end of treatmeot.[9, lO]; RESULTSlI, 12]. The depressed padeors in both groups presented very similar haselineffADrOPOULOS [14] have esta- values cf the various resrs. Tables I, I! and II! show the scOte rrend from theosomes are related to physical1 psychodiagnostic tesrs on eaeh occasion both for che group rreated with sul-;vith biological membranes. piride and hypothalamic phospholipids (Group A) and for the group treatedf hypochalamic origin, charac- with sulpiride alone (Group B). hydrocarbon chains and nega- Tbc score tread evaluated on the 7th day "ld, at the end of trearment by means of Cassanos test revealed a Clear imprbvemeot in boch- groups. Howevet, the percentage improvernent in the group in V{hich phospholipid liposomes were associated with the sulpiride was as high as 16.2 %, while in che group treated with sulpiride alone it was 8.7 %., included in the stiIdy. For An eveo clearer improvemeot was found in the resulrs of boch Zung<gnostic Criteria (ROC) [15]. and Hamilton tesrs in padenrs who bad been treated wich hypothalamicof Hamiltons scalIe, Cassanos phospholipid liposomes together with sulpiride. This improverneot was ofI Wittenborns test for schizo- 15.2 % and 35.1 % respecrively, against the 6 % and 17.7 % achieved withepression and 15 from schizo- sulpiride alone (Fig. 1).Acta Therapeutica lO (1984) Acta Therapeutica lO (1984) 135 --"+"--
  4. 4. El E. "AGUGLIA; C. CALANDRA, D. MAUGBRI. V. RAPISARDA , . 1-. t·,i... TABLE II: S:ore "end jrom Zur. .phoJpholipid JipOJOI7WJ TABLE I: $&018 J1fma tram CatJlJtJ<l.J test {or JepreISeJ p4lients weated with JUlptride Ima _..pbosphòlipid liposr;nu,s (G...p A) mul sulpirnte oIcn. (&aup B). .: .~: GROUP A Initials Age IniU.I, Age Baseline Day 7 End of treatment B.L. 37 C.V. 33 B.L. 37 50 74 49 A.R. 32 C.V. 33 99 46 38 B.R. 52 A.R. 32 93 40 45 e.R. 36 B;R. 52 60 38 43 Cur. 37 e.R. 36 64 60 42 e.G. 41 Curo 37 90 60 43 Costo 20 e.G. 41 95 95 84 R.e. 20 Costo 20 60 41 45 M.G. 49 R.C. 20 77 79 63 M.G. 49 98 92 72 I .. l : Means . Means 78.6 62.5 52.4 i _ L: ± S.D. ± S.D. 18.63 21.5 15.3 r j GROUP B I I Initials Age Day 7 j .. IniUals A8e BaseUne End of trcatment A.L. 29 I M.G. 43 A.L. 29 86 88 81 I 38 T.G. M.G. 43 75 71 .- 6S V.A. 32 ·T.G. 38 62 58 54 P.G. 41 V.A. 32 92 84 76 P.G; 41 84 80 72 Means .. , ± S.D. Means 79.8 76.2 69.6 . ; ± S.D. ·11.67 11.19 10.5 I i,. I ," ! ! Acta Therapeutica lO (198 136 Acta Therapeutica lO (1984)
  5. 5. EFFEcr OF .HYPOTHALA,MIC PHQSPHOLIPID LIPOSOMES <DA TABLE II: $&o1e weml tram Zun~s test lor àep1(JiSQJ, pt1tiqnts rea/ed. w;th sulpiriJe atul phospholipit! Uposomus (Gt-Ofl.P A) and sù/pi;;de tlkntl (.Group B). l patiemts trealeJ lUi/h Ju/piride Ima p;rid. .Jcn. ( Group B). GROUPA lnitials Age Baseline Day 7 En~ or trcatment )ay7 End of treatment B.L. 37 38 55 30 C.V. 33 56 37 30 74 49 A.R. 32 63 25 36 16 38 B.R. 52 52 33 30 lO 45 e.R. 36 47 38 33 i 18 43 Curo 37 40 48 3g ;O 42;O e.G. 41 58 53 50 43 Costo 20 31 38 2915 84Il 45 R.e. 20 65 62 so1912 63 72 ·I·"i· "" M.G. Means 49 67 52.7 56 44.5 51 37.7 I52.511.5 52.4 15.3 l. ± S.O. 12.34 11.95 9.17 I l " ..•. ?: lnitials Age GROUP B BaseIine Day 7 End of treatment I [ ·Il~)ay7 End of treat.ment A.L. 29 43 48 39 M.G. 43 68 63 5618 81 T.G. 38 51 45 41I 65 i:;8 54 V.A. n ·62 57 49 1 P.G. .41 37 35 3414 76 -:.::.IO 72 Means 52.2 49.6 43.8 ± S.O. 12.87 10.85 8.706.2 69.61.19 10.5 ..:1... :1 Acta Therapeutica lO (1984) 137Acta Therapeutica lO (198~___-":i~lr"_
  6. 6. . lr:.o j, ... _--_._~- I E. AGUGl:.IA. C. CALANDRA, D. :MAUGERI. V. RAPISARDA E I I 30 TABLE III: S&o~e trend from Hamil/(m.JJ test far Jepresml p8tìents J1eatea with su/ijirid(l ami ihospholipid Iiposomes (Gro"" A) ami ndpiriJ, al.ne (Group B). . 20 Clssan 16.ZO/. GROUPA .. lnitials BaseIi~e 10 , Age J}ay7. End or treatment i , B.L. C.V. 37 33 11 33 12 15 5 7 l ,[ A.R. B.R. 32 52 30 19 IO 8 8 2 ~ Sulpi , C.R. 36 23 12 8 Curo , 37 38 23 7 O Sulpi C.G. I 41 33 28 28 CeSt. 20 15 16 14 R.C. 20 12 IO 9 Percentage improvement in M.G. 49 30 31 19 Means 24.4 16.5 10.7 "s.o. 9·70 8.05 7.7 ·GROUP B 100 InitiaIs Age Baseline Day 7 End or treatment 80 A.L. 29 32 28 23 M.G. 43 26 2S 18 60 T.G. 38 23 26 16 ! V.A. 32 19 21 16 40 P.G. 41 27 24 20 " .1 20 • Means " S.O. 25.4 4.82 24.8 2.58 18.6 2.96 ng/ml • E -.- Trend of plasm 138 Acta Therapeulica lO (1984) Acta Therapeulica lO (198 .::~ i X ,,::--.;!.. •<
  7. 7. .RDA EFFECT QP HYPOTHALAMIC PHOSPHOLIPID LIPOSOMES ., HamlUon 35.1% 30 rQfS~d pt/tienu /re4leJ. with tulp"itiae ",Ipiride aùJne (Group B). 20 :Jay 7 End of treatment lO 12 S IS 7 IO 8 " 8 2 12 8 ~ Sulplride + Phospholipld tiposomes!3!8 7 D Sulpiride 2816 14 ,~;;. Fig...IO 9 Percencage improvement in the psychodiagnostic tests in tbe 2 8J:oups tA and B)Il 19 of depressed patients. 6.5 10.7 8.05 7.7 ,e 100lay7 End of treatment ~ 808 23 :.i /:5 18 60:6 16 1 ~l:1 16 " 40:4 20 - 204.82.58 18.6 2.96 "!l/m! i B 7 .140 29 99 Sulpirlde _: Sulpiride + Phosphollplds Fig. 2 T:end of plasma prolactin leye1s in depressed patients. :1 " . . . ~, " "Icta Therapeutica lO (1984) "T :1 Acta Therapeutica lO (1984) 139 ~-----t-""""
  8. 8. B. AGUGLIA, C. CALANDRA; n",-MAUGERI. V. RAPISARDA The increase in se"rum lrolactin levels induced by sulliride was not i; ~" influenced by adjuvant treatment with hYlothalamic lhoolh,?lipid lilosomes " ~" (Fig. 2). ,-i.; i. . ,.: o In the schizolhrenic latients treated with haloperidol, the evaluation }" of the symltomatological trends was carriecl out by means of Wittenborns test. The lrolaetio trend was also evaluated. Table IV shows the values oh· tained using thls test on the various examinations carried out on the two grouls of patients. In the latients who had undergone adjuvant theraly with phos. lholilid Iiposomes, a statistically sigoificant imlrovement was found in 7 of ·the 9 subtests with the.,Wlttenhorn test. The. imlrovement obtained was sigoificant in only one of the sub-tests in latients treated with haloperidol alone. A global evaluation bf the sub-tests a1so revealed a greater pereentage imlrovement in the latients treated with lhoolholipid liposomes (Fig. 3). In addition, in tbe schizolhrenic larients treated with both haloperidol. "and hypothalamic lhospholilid Iiposomes the plasma lrolactin levels tended -.-;". to decrease, wbile in the patients treared with haloperidol alone they continued to increased (Fig. 4). 29.55% 39· 20 lO ~ O Haloperidol Haloperidol + Phospholipids j I-"-j_~---"_~--,-M.:.",---~,- ;j Fig. 3 Percentage improvement in the global value ai the Wittenbom test. ù:;Èo:;Èui:;È: CliClia:ip.;~c.h 140 Acta Therapeutica lO (1984) i ,.
  9. 9. ~ ~ ii .. " 0-0 !l" " ~ " ,.,. go .... s- ~ o» a. ~ -1?-. r:t B :> (b"~ .g (l ~ g -o .g tl. f.l~ g- tg..(i g r:o·a s..~ g:" ~. [ :T tr ,. !=l ~ l:S <: _.... t O" (ti ~ a: IO a. .g:a. ti) Ste:. "ttrb~(D_<:o ~§~"P-.<:=?ì~ e..-g ~ e. g. p- P-.., ~. [g~:;g&~s: g. B~~".g f O ~ ii S &_p- g il ~ ~ 1~~~8~oJ2. ..... ~~O::l ~g-~~ $O "t-. g.~ g,~ ì~...IO ~ ..., "" p- "li " ~_ &l", eq. 8.. ;1. ~ " !=i!;! " f~Q O O- ~ i;j8~ o ~ Q S!l !:l. ~. fl ~ a. S "Oa~Ofllo & "" " g. ~ a.a.s. :~ ., OQ.P-. li: 1 ..... g- O o g <:l.O~ Y,. $2.. ~ la. { --g r:r fA" 8 =g LI o ( ...", .------~_::-- ::,~". ..:: .~;:; ::::-:-:. ,..,:: i-: ,.., "r.·>:·<;,"· O" . "l,·:: .,;,", o". ,. ,.-.... _·,;"":.:-":,:,." •• ,..;::1e.~ TABLE IV: Score "end Irom lflittenborns test in schizophrenic patients Ireatea wi/h haloperidol (#fa phospholipid uposomcs (Group A) and haloperidol ttlone (Group Bi GROUPA Schizophrenic Paranoic Ebepbrenic Anxiety Hysteria Mania Depression exitabitity Paranoia schizophrenia schizophrenia Obsession Nam. BL 7 End BL 7 End BL 7 End BL 7 End BL 7 End BL 7 End BL 7 End BL 7 End BL 7 End S.C. 6 3 3 2 2 2 6 5 4 O O O 7 5 2 3 3 2 3 3 2 7 5 4 2 2 2 S.M. 8 7 5 6 4 4 7 7 5 3 3 4 9 9 6 lO lO 6 lO lO 6 lO lO 6 5 5 4 B.G. 5 5 4 2 l l 1 l l 6 6 3 7 6 5 9 7 4 9 7 4 2 2 l 3 3 2 P.M. 2 2 l 2 l l l O O 4 3 3 6 4 4 8 5 5 8 5 5 4 3 3 2 2 2 F.S. ·8 7 5 5 4 2 3 3 2 5 4 2 7 7 4 8 6 4 8 6 4 4 3 2 3 3 3 C.M. 5 3 2 3 3 2 5 5 2 2 l l 6 5 4 8 7 5 8 7 5 5 5 4 5 5 4 SoN. 4 4 2 2 . 2 1 3 2 2 6 6 5 6 5 5 8 7 5 8 7 5 5 5 4 3 3 3 L.C. 8 5 4 5 5 4 6 4 4 3 3 2· 8 7 4 9 7 3 9 7 3 4 4 3 4 4 3 P.C. 3 3 2 3 2 2 4 3 3 5 5 4 8 7 3 lO 7 4 lO 7 4 6 6 3 3 3 3 Se.C. 3 4 2 2 2 l 3 2 2 4 3 3i 5 5 4 8 5 4 ·8 5 4 3 3 2 1 l l Means 5.2 4.3 3.0 3.2 2.6 2.0 3.9 3.2 2.5 3.8 3.4 2.7 6.9 6.0 4.1 8.1 6.9 4.2 8.1 6.4 4.2 5.0 4.6 3.2 3.1 3.1 2.7 P ( 0.001 ( 0.05 N.S. N.S. , 0.01 , 0.001 , 0.001 ( 0.01 ( 0.05 GROUPB .... ; Schizophrenie Paranoic Ebephrenic Anxiety Hysteria Mania Depressioi exitabiIity Paranoia scbitopbrenia schizophrenia Obsession Name BL 7 Ena BL. 7 End BL 7 End BL 7 End BL 7 End BL 7 End BL 7 End BL 7 End BL 7 End M.R. 8 6 5 2 l 2 l l l 6 6 4 3 4 5 8 6 7 8 6 7 3 3 2 6 3 3 D.L. 5 3 3 2 2 2 4 3 3 2 3 2 4 4 3 3 l 2 3 3 2 6 5 3 3 3 3 L.A. 3 2 2 2 3 2 6 6 5 O O O 7 7 6 lO 8 8 9 8 6 4 3 2 l l l L.G. 4 4 2 3 3 l ·1 O O 3 3 3 l 2 l 9 7 5 9 8 7 5 5 4 4 4 3 C.S. 4 5 4 3 4 3 2 3 3 5 4 3 3 2 3 3 3 ·2 4 2 3 4 4 3 2 2 2 Means 4.8 4.0 3.2 2.4 2.6 2.0 2.8 2.6 2.2 3.2 3.2 2.4 3.6 3.8 3.6 6.6 5.0 4.8 .6.6 SA 5.0 4.4 4.0 2.8 3.2 2.6 2.4 P N.S. N.s. N.S. N.S. N.s. N.S. N.S. < 0.01 N.S. BL = Baseline 7 =Day7 End = End of rreatment N.S. = Not significaoe
  10. 10. B. AGUGLIA, c. CALANDRA. D. MAUGERl, V. RAPISARDA (5] NIEDERER, W., :R.ICHARDS humour production. 100 (6] CASACCHIA., M., .Mroo, d.; ! BO POMPEI, P" FJlAJEsE.: In: Newoendocrine I A. Agnati Eds., E1s~ I 60 40 _ ....... ...-:. {7] O!U.ANoo, P., CERRrm, F., lipids administeJ:ed 1 I 20 ~~ .. "," : [8] LEON, A., TOIiPANO, G. - into mice brain lho: i ng/ml L.~.:- B __-::::-_-:,:":,,,_-:::::-,: 7 0 14 6 29- 911 . (9] BRUNT, A" LEoN. A., Bo} free glucose in mire. ! [lO] BRVNC, A., TOFFANO, G., : ! Haloporidoi phatidylserine liposo Haloporidol + Pbospholipids [I1J POLLERI, A., ROtA!NDI, I N1NC, A., MURIAUx Fig. 4 cerebrol dopamine lì T.rend of plasma prolactin Ievels in schizophrenic pacients. dopaminergic nervot [12J TOIiPANO, G., !:BaN, A., : CONCLUSION somes Da the reguJa Lipids, 81 : 407-41< [13] GRF.OORIADIS, G. - The , The results show a clear improvement in al! patients and they are there- N.w England J. af . fore in agreement with pub)ished literature on SuIpiride end haloperidoL [14J PAJ>AHADIOPOlJI.OS, D. - i" The concurrent use of hypothalamic phospholipid liposomes does not mode! membranes. i , Nonh Holland Pubi have a negative effect on the therapeutic potential cf the lWO drugs, but [15J SPITZER, R.L., ENDwon,; . rather this therapentic effect is strengrhened as shown by the improved results Research Ed., New Y; ;.i,::~" obcaìned in the vadous. psychodiagnostic teslS in both depresse<! end schizo-r··;" . i phtenic patients. With regard to pròlaetin levels, the increase induced by sulpidde was not Address of the Gbthol: Dr. E.) . affected by treatment with phospholipid liposomes; this did how~ver occnr in RESUME patients treated with haloperidoL !.es auteurs ont évalué thalamiques chez des patie< BIBLIOGRAPHY schizophrènes trairés par lh: (1] DmVY. P., BoBAN, J., Cou.ARD. J., PJNCHAlU), H. - Etude et expérimentation clini~ ceux observés dans deux gr ques du RIG25 ou halopeddol. nouveau neuroleptique et neurodysleptique. et traités par les memes agel A&ta Neurol. PSYchi4tf., Belgi&al 59 : 337 (1959). rée à laide des teslS de H: (2] SARTESCHl. P., CONTI. I.., CAssANo, G.D. - Sulpicide in the ueatment of psychocic plasmatiques en p,olaetine . and neurotic syndromes. In: Sulpiride and orber benzamides. ltalian Brain Res. Found. Fress, Milan (1979). mel!e des phospholipides l [3J ULETI, G.H., HEUSlD., A.F., WOtlD, T.J. - The effects of psychorroplcs drugs on par 105 deux psychotropes. the EEG af the cbJ:onic psychotic patients. In Application of EEG in PsychiatrY~ le.s résilltats démontrer Duke Univo P.ress. North Cacolioe (1965). diques hypotbalamiques SUr (4] FINx, M. - Quantitative EEG and Human psychopharma.cology. Applica.rion of EEG souS. forme dun renforcemeJ in Psychiatry. Duke Univo Press, North Caroline (1965). 142 Acta Therapeutica 10 (1984) Acta Therapeutica lO (]98.
  11. 11. EFFECT OF HYPOTHALAMlC PHOSPHOLIPID LlPOSOMES DA [5J NIEDERER, W" RICHARDSON. B.P.• DoNATSCH, P. - Hormonal concrol of aqueous homour prodnaion. Exp. Eye Ret., 20 : 329 (1975). (6J CASACClUA., Mo. MEoo. d.:C:.utCHEDI, F., DI C:EOr.m•.M., F.ALASCHI. P.) Rocco. A.. POMPEI, P., F1wEsE, G. - Neuroendocrlne side effects of antipsychotic therapy. In: Neuroendocrine Correlates in Neurology and PsychiattY. RE. Muller and A. Agfioli Ed,., E!sevier, 211-224 (1979). _ .. __ ..tIo (7] ORLANDO, P., CERRtro, P., ZI!uu.I, P. - The fare of double·lahelled braio phospho- :~ .. Jipid, admioisrered ro mice. Il Parma"" 30: 451-458 (1975)•. (8] LEON, A.) TOPFANO) G. -.I!ossible .cole of BCPL in enhanciog 32 1>i iorozporatioo inro mie< b",in phospholipid. Ad•• Exp. Med. Biol., 72: 307-313 (1976). [9J BR.UNI, A., !.EoN. A.• BoA:RA"J1O, E. - .:Bffecr of polar lipids on ccrebral content of free gluco« in mice. Ad•. Exp. Mad. Bio/., 72 : 271-2g3 (1976). [lO] BRUNI, A., Topp.A:No, G., l.Eo.N. A.• BoA!R.Aro. E. - Pha.rmacological effects of phoo- phacidy1serine lipooomes. NaJura, 260 : 331·333 (1976).holipids [l1J POLI.ERI, A.• R01AlNDI. E., BA.R!R:EccA. T., GlA!RRossr. R., .M.ASTURZO. P., GAU.A- A.) MUR.JALDO, G., NIZZQ. M.c. - Effeet of b.ra.in phO$pholopids on NlNl, cerebral doparnine and on proIacdn serum leveIs. Symposium on non striata!!ophrenic patients. dopamine.rgic nervous tissue. Foit Village (1976). [12J TOFFANO, G.• lEoN, A., SAvolNl, G., 01U.AND0. P. - Effea of phospholipid lipo- somes 00 the regulacion cf ce.rebral metabolism. pft11&tion 4nd Bi()synthe,Sù of IJpuu, 81: 407-418 (1977). [13] G. - The car.rier potential cf Iiposomes in biology and medicine. Thq GREOORIAOIS,II patients and they are thet" Net" Engidnd J. oi Med., 295: 765·770 (1976).lpiride and haloperidoI. (l4] PAPARADIOPOULOS, D. - Calcium·induced phase change and fusion in nawml andpholipid lipooomes does nor mode! membranes. In: Membran Fusion. G. Poste RIld G.L. Nicolson BIs., North Hnllattd Publihio8, Amsrerdam; 765-790"(1978).:odal of rbe <wo drugs, but [15J SPrr.2ER, R.L., EN:ollCOIT, J., ltoBJNs. E. - Reseatch diagnostie criteria. Biometrie~DWn by the imptoved tesults ReSearch Ed., New York (1977).n both depressed and scnìzo- Address of the ailthor: Dr. E. AGUGLIA, Via Etneo, 740, 95128 Catania <Ita/y). :I. induced by snlpiride was not.es; tbis did however occnr in RESUMB Les anteurs onr évalué lefficacité des lipooomes phospbolipidiques hypo- thalarnlques che>: des patients déprimés traités par le sulpitide et chez des schizophrènes rraités par lhalopéridol en comparant les résnlrats obtenus avec- Etude et expérimentatibn clini~ ceux observés dans deux groupes de contròle souffrant des m~mes maladiesJ.euroleptique et neurodysleptique. et traités par les m~mes agents psychotropes. La qualité des résultats fut mesu·59). rée à laide des tests de Harnllton, Cassano, Zung et Wittenborn. Les talIX.ride in the trearmene of psychoclc plasmariques en prolacclne furenr suivis afin de détecter une influence éven- other benzamides. Italian Baia tnelle des phospholipides hypothalamiques sur lhyperprolaclinémie induite~ effects of psychotroplcs drugs oa par les deux psychotrQPes. Applicacion of EEG in Psychlatry, Les résulrats démoiIrrenr une aclion favorable des liposomes phospholipi· diques hypothalamiques sur les effets thérapeutiques des deux psychotropespharmacology. AppHcation cf EEG sous forme dun renfotcement de leur aetioo.,lioe (1965)..cta Therapeutica lO (1984) Acla Therapeutica lO (1984) 143 ---_._-_ .

×